Every material Form 8-K Medpace filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Medpace reported third-quarter 2024 revenue of $533.3 million, up 8.3% from a year earlier, and GAAP net income of $96.4 million, or $3.01 per diluted share, versus $2.22 in the prior-year quarter. Net new business awards fell 12.7% to $533.7 million, but the net book-to-bill ratio was 1.00x and backlog rose 8.8% to $2,927.4 million. The company forecast full-year 2024 revenue of $2.090 billion to $2.130 billion and GAAP diluted EPS of $11.71 to $12.09.
Q3 2024 revenue was $533.3 million, up 8.3% from $492.5 million; EBITDA rose 31.7% to $118.8 million.
Q3 2024 GAAP net income was $96.4 million, or $3.01 per diluted share, versus $2.22 a year earlier.
Net new business awards were $533.7 million, down 12.7% from $611.5 million; backlog was $2,927.4 million as of September 30, 2024.
2024 guidance: revenue of $2.090 billion to $2.130 billion and GAAP diluted EPS of $11.71 to $12.09.
Medpace reported second quarter 2024 results on July 22, 2024, with revenue up 14.6% year over year and GAAP net income of $88.4 million, or $2.75 per diluted share, versus $1.93 a year earlier. The company also gave full-year 2024 guidance of $2.125 billion to $2.175 billion in revenue and $11.24 to $11.93 in diluted EPS, but net new business awards fell 4.1% in the quarter.
Q2 2024 revenue was $528.1 million, up 14.6% from $460.9 million; EBITDA rose 34.2% to $112.3 million.
Q2 2024 net new business awards were $551.0 million, down 4.1% from $574.8 million, for a net book-to-bill ratio of 1.04x.
2024 guidance: revenue of $2.125 billion to $2.175 billion, GAAP net income of $361.0 million to $383.0 million, and diluted EPS of $11.24 to $11.93.
No share repurchases were made in Q2 2024; $308.8 million remained under the authorized program as of June 30, 2024.
Medpace director Ashley M. Keating resigned from the Board effective June 30, 2024, stating no disagreement with the company. The Board appointed Dr. Dani S. Zander to fill the resulting Class III vacancy effective July 1, 2024, and to the Nominating and Governance Committee.
Ashley M. Keating resigned from the Board effective June 30, 2024, with no disagreement on operations, policies or practices cited.
Dr. Dani S. Zander was elected to the Class III vacancy effective July 1, 2024, serving until the 2025 Annual Meeting of Stockholders.
Dr. Zander joined the Nominating and Governance Committee effective July 1, 2024.
Dr. Zander received a director equity award of an option to purchase 824 shares at the July 1, 2024 closing price, with a seven-year term.
Medpace reported first-quarter 2024 revenue of $511.0 million, up 17.7% from a year earlier, and GAAP net income of $102.6 million, or $3.20 per diluted share, versus $2.27 a year earlier. The company also forecast full-year 2024 revenue of $2.150 billion to $2.200 billion and GAAP diluted EPS of $10.79 to $11.47, and reported no share repurchases in the quarter.
Q1 2024 revenue $511.0 million, up 17.7% from $434.1 million; backlog rose 18.2% to $2,907.1 million.
Q1 2024 GAAP net income $102.6 million, or $3.20 per diluted share, vs. $72.9 million, or $2.27, in Q1 2023; EBITDA rose 24.6% to $115.7 million.
2024 guidance: revenue $2.150 billion to $2.200 billion; GAAP net income $347.0 million to $369.0 million.
No share repurchases in Q1 2024; $308.8 million remained under the authorized program at March 31, 2024.
Medpace Holdings and its subsidiaries signed Amendment No. 6 to the loan documents for its unsecured credit facility with PNC Bank, National Association, on March 28, 2024. The amendment sets the aggregate principal that may be borrowed under the line of credit at up to $10 million and extends the revolving credit note's expiration date to March 31, 2025. The filing does not state the prior borrowing limit, and the change is administrative in nature.
Amendment No. 6 to Loan Documents dated March 28, 2024, with PNC Bank, National Association
Aggregate principal borrowable under the line of credit set at up to $10 million
Revolving credit note expiration extended to March 31, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Medpace filing is on SEC EDGAR ↗. 8-K briefs of other companies →